Plasmodium vivax treatment, Krintafel, receives FDA nod
by News Desk from Outbreak News Today on (#3VBMY)
GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection. Krintafel is an 8-aminoquinoline derivative with ["]
The post Plasmodium vivax treatment, Krintafel, receives FDA nod appeared first on Outbreak News Today.